Acute ischemic stroke: New strategies for management and prevention

Geriatrics

Volumn 54, Issue 8, 1999, Pages 47-52

  Furlan, Anthony J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PROUROKINASE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; WARFARIN;

BLOOD CLOT LYSIS; BRAIN ANGIOGRAPHY; CAROTID ARTERY DISEASE; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CORONARY STENT; DRUG EFFICACY; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; BRAIN ISCHEMIA; EMERGENCIES; HUMANS; RISK FACTORS; TIME FACTORS;

EID: 0032798129     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333(24):1581-7.
2. Marler JR, Jones PW, Emr M (eds). Rapid identification and treatment of acute stroke. Proceedings of a national symposium. Bethesda, MD: National Institutes of Health, 1997:37-439.
3. Furlan AJ, Higashida R, Wechsler L, Schulz G. PROACT II: Recombinant prourokinase (r-ProUK) in acute cerebral thromboembolism. Initial trial results. Stroke 1999; 30:234(abs).
4. Sherman DG for the STAT writers group. Defibrinogenation with Viprinex (ancrod) for the treatment of acute ischemic stroke. Stroke 1999; 30:234(abs).
5. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349 (9065):1569-81.
6. Bruno A, Biller J, Adams HP Jr., et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 1999; 52(2):280-4.
7. Plehn JF, Davis BR, Socks FM, et al Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. Circulation 1999; 99(2):216-23.
8. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent. Events Trial investigators. N Engl J Med 1996; 335(14):1001-9.
9. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and, a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19):1349-57.
10. Papademetriou V, Narayan P, Rubins H, Collins D, Robin S. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Veterans Affairs HDL Intervention Trial. Am Heart J 1998; 136(4 Pt 1):734-40.
11. North American Symptomatic Carotid Endarterectomy Trial collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325:445-53.
12. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273(18):1421-8.
13. Kutner M, Nixon G, Silverstone F. Physicians' attitudes towards oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991; 151(10):1950-3.
14. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038):1329-39.
15. Sivenius J, Cunha L, Diener HC, et al. Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. Acta Neurol Scand 1999; 99(1):54-60.